🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. SPD503-AM

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule completed

    1 trial

  2. SYR-322-MET

    Takeda Pharmaceuticals International AG

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  3. SYR-472

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  4. SYR-472

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  5. Soticlestat

    Takeda Pharmaceuticals International AG

    Dravet Syndrome (DS)

    phase 3 small molecule terminated

    3 trials

  6. Spironolactone

    Takeda Pharmaceuticals International AG

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  7. TAK-003

    Takeda Pharmaceuticals International AG

    Dengue Fever

    phase 3 mab completed

    1 trial

  8. TAK-019

    Takeda Pharmaceuticals International AG

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  9. TAK-279

    Takeda Pharmaceuticals International AG

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  10. TAK-279

    Takeda Pharmaceuticals International AG

    Plaque Psoriasis

    phase 3 small molecule active

    3 trials

  11. TAK-330

    Takeda Pharmaceuticals International AG

    Coagulation Disorder

    phase 3 small molecule active

    1 trial

  12. TAK-438

    Takeda Pharmaceuticals International AG

    Duodenal Ulcer

    phase 3 small molecule completed

    2 trials

  13. TAK-438

    Takeda Pharmaceuticals International AG

    Gastric Ulcers

    phase 3 small molecule completed

    4 trials

  14. TAK-438

    Takeda Pharmaceuticals International AG

    Erosive Esophagitis

    phase 3 small molecule completed

    4 trials

  15. TAK-438

    Takeda Pharmaceuticals International AG

    Gastric Ulcer

    phase 3 small molecule completed

    4 trials

  16. TAK-438

    Takeda Pharmaceuticals International AG

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  17. TAK-438

    Takeda Pharmaceuticals International AG

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  18. TAK-536

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  19. TAK-536CCB

    Takeda Pharmaceuticals International AG

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  20. TAK-536TCH tablet

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  21. TAK-559

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  22. TAK-559 and glyburide

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  23. TAK-559 and insulin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  24. TAK-559 and metformin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources